Access to Healthcare on a Global Scale
We’re committed to providing patients and their families with transformative medicines, as we aim to understand the needs and experiences of those we serve.
A Phase 2 study investigating the effect of EDP1815 in the treatment of mild to moderate plaque psoriasis
Phase 1/2, randomized, placebo-controlled trial conducted in two parts. Part A will evaluate the safety and tolerability of EDP2939 in healthy volunteers. Part B will evaluate the safety, tolerability and preliminary efficacy in adults with moderate psoriasis. The primary endpoint of Part B is the superiority of EDP2939 as compared to placebo on the proportion of participants with moderate psoriasis achieving a PASI-50 response.
A Phase 2 study investing the effect of EDP1815 in the treatment of mild, moderate and severe atopic dermatitis
If you have questions about our clinical trials, please contact email@example.com.
Read about our commitment to patients from some members of our team.